Search

Background: In the Caribbean region, a notable difference in HPV-prevalence and genotypes distribution between the islands is observed. Recently we found in Curaçao a low incidence of HPV16 and 18 in cervical cancer compared to the standard world population. We aimed to determine HPV-prevalence, HPV-genotype distribution and associated risk-factors in women from Curaçao., Methods: 5000 women aged 25-65 years were randomly selected from the national Population Register. HPV was detected by means of GP5+/6+PCR EIA and GP 5+/6+amplimers from HPV-positive samples were genotyped with a reverse hybridisation assay. We also collected personal data and data on risk-factors., Results: 1075 women were enrolled in the study. Overall HPV-prevalence was 19.7%. Most frequent genotypes were HPV16 (2.3%), 35 (2.1%) and 52 (1.8%). Twenty-seven women detected with abnormal cytology (i.e.≥ASC-US) were referred for biopsy. In women with normal cytology (n = 1048), HPV-prevalence was 17.9% and the most common high-risk HPV (hrHPV)-types were HPV35 (2.0%), 18 (1.8%), 16 (1.5%) and 52 (1.5%). The highest HPV-prevalence (32.8%) was found in the age-group: 25-34 (n = 247). HPV positive women started sex at a younger age (p = 0.032)., Conclusions: HPV-prevalence in the overall population is high and HPV16 was the most common genotype followed by 35 and 18. In women with normal cytology HPV35 is the most common genotype followed by HPV18, 52 and 16. The high HPV-prevalence (32.8%) in women of 25-34 years argue for introduction of cervical cancer prevention strategies. HPV-type distribution found in Curaçao should be taken into account when considering the choice for prophylactic vaccination., Competing Interests: Desiree J. Hooi, Birgit I. Lissenberg-Witte, Maurits de Koning, Herbert M. Pinedo, Gemma Kenter, Igor Gomes Bravio, Kim Ardts, Edlyn Benita have no competing interests. Chris JLM Meijer has received speakers’ fee from SPMSD/Merck, served occasionally on the scientific advisory board (expert meeting) of Qiagen, SPMSD/Merck. He has been co- investigator on a Sanofi Pasteur MSD sponsored trial. He is part-time director of and minority stock holder of Self-Screen B.V., a spin off company of VUMC, and has a very small number of Qiagen shares. Until April 2016, he had minority stock of Diassay B.V. Wim Quint has obtained projects from GSK and Qiagen and is stockholder of DDL Diagnostic Laboratory. Johannes Berkhof has received consultancy fees from Roche, GlaxoSmithKline, and Merck/SPMSD and received travel support from DDL. All fees were collected by his employer. This does not alter our adherence to PLOS ONE policies on sharing data and materials.